Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0043-1777865
Review Article

Localized Rectal Cancer: Indian Consensus and Guidelines

Viraj Lavingia
1   Department of Medical Oncology, HCG Cancer Center, Ahmedabad, Gujarat, India
,
Shefali Sardana
2   Department of Medical Oncology, Max Institute of Cancer Care, Max Superspeciality Hospital, New Delhi, India
,
Mansi Khanderia 
3   Department of Medical Oncology, SPARSH Hospitals, Bangalore, Karnataka, India
,
Niharika Bisht
4   Department of Radiation Oncology, Army Hospital Research and Referral, New Delhi, India
,
Amol Patel 
5   Department of Medical Oncology, Indian Naval Hospital Ship Asvini, Mumbai, Maharashtra, India
,
Venkata Pradeep Babu Koyyala 
6   Department of Medical Oncology, Tezpur Cancer Center, Assam Cancer Care Foundation, Bihuguri, Assam, India
,
Harsh Sheth
7   Department of Advanced Genomic Technologies Division, FRIGE Institute of Human Genetics, Ahmedabad, Gujarat, India
,
Anant Ramaswamy
8   Department of Medical Oncology, Tata Memorial Centre (HBNI), Mumbai, Maharashtra, India
,
Ashish Singh
9   Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India
,
Ashwin deSouza
10   Department of Surgical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sneha Bothra Jain 
11   Department of Medical Oncology, Mittal Institute of Medical Sciences, Bhilai, Chhattisgarh, India
,
Mukta Mahajan
12   Department of Radiodiagnosis, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India
,
Shruti Gohel 
13   Department of Medical Oncology, HCG Cancer Centre, Ahmedabad, Gujarat, India
,
Aparna Parikh
14   Department of Medical Oncology, Mass General Cancer Centre, Boston, United States
,
Gina Brown
15   Department of Gastrointestinal Cancer Imaging, Imperial College, London, United Kingdom
,
Bhawna Sirohi 
16   Balco Medical Centre, Raipur, Chhattisgarh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The rising incidence of colorectal cancer (CRC) in India, particularly the prevalence of rectal cancer over colon cancer (0.7:1), has been a growing concern in recent decades; especially notable is the trend of increasing cases among young CRC patients. Given the diverse treatment approaches for rectal cancer globally and the varying economic capacities of patients in low to middle-income countries (LMICs) like India, it is essential to establish consensus guidelines that are specifically tailored to meet the needs of these patients. To achieve this, a panel comprising 30 eminent rectal cancer experts convened to conduct a comprehensive and impartial evaluation of existing practices and recent advancements in the field. Through meticulous scrutiny of published literature and a consensus-building process that involved voting on pertinent questions, the panel formulated management strategies. These recommendations are the result of a rigorous, evidence-based process and encapsulate the collective wisdom and judgment of leading authorities in the field.

Keywords

Indian consensus and guidelines - early rectal cancer - MRI - MSI

Authors' Contributions

Bhawna Sirohi and Viraj Lavingia were involved in concept and design. All the authors have helped in definition of intellectual content, literature search, manuscript preparation, manuscript editing, and manuscript review.


Patient Consent

No, as in this article, the guidelines presented are derived from a comprehensive literature review and expert consensus.


Supplementary Material



Publication History

Article published online:
09 February 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Google Scholar
  • 2 Mathur P, Sathishkumar K, Chaturvedi M. et al; ICMR-NCDIR-NCRP Investigator Group. Cancer statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol 2020; 6 (06) 1063-1075
    CrossrefPubMedGoogle Scholar
  • 3 ESMO Clinical Practice Guidelines. Methodology. Accessed December 6, 2023 at: https://www.esmo.org/guidelines/esmo-guidelines-methodology
    Google Scholar
  • 4 National Cancer Institute. Cancer stat facts: colorectal cancer [Internet]. [cited 2023 Mar 1]. Accessed December 6, 2023 at: https://seer.cancer.gov/statfacts/html/colorect.html
    Google Scholar
  • 5 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72 (01) 7-33
    Google Scholar
  • 6 Montminy EM, Zhou M, Maniscalco L. et al. Contributions of adenocarcinoma and carcinoid tumors to early-onset colorectal cancer incidence rates in the United States. Ann Intern Med 2021; 174 (02) 157-166
    CrossrefPubMedGoogle Scholar
  • 7 United States Preventive Services Taskforce. Colorectal Cancer: Screening [Internet]. [cited 2023 Mar 1]. Accessed December 6, 2023 at: https://uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
    Google Scholar
  • 8 Dasari A, Morris VK, Allegra CJ. et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 2020; 17 (12) 757-770
    CrossrefPubMedGoogle Scholar
  • 9 Muller C, Lee SM, Barge W. et al. Low referral rate for genetic testing in racially and ethnically diverse patients despite universal colorectal cancer screening. Clin Gastroenterol Hepatol 2018; 16 (12) 1911-1918.e2
    CrossrefPubMedGoogle Scholar
  • 10 Monahan KJ, Bradshaw N, Dolwani S. et al; Hereditary CRC guidelines eDelphi consensus group. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 2020; 69 (03) 411-444
    CrossrefPubMedGoogle Scholar
  • 11 Abu-Ghazaleh N, Kaushik V, Gorelik A, Jenkins M, Macrae F. Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: systematic review and meta-analysis. Genet Med 2022; 24 (05) 971-985
    CrossrefPubMedGoogle Scholar
  • 12 Seppälä TT, Dominguez-Valentin M, Sampson JR, Møller P. Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD). Fam Cancer 2021; 20 (01) 35-39
    CrossrefPubMedGoogle Scholar
  • 13 Dominguez-Valentin M, Sampson JR, Seppälä TT. et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med 2020; 22 (01) 15-25
    CrossrefPubMedGoogle Scholar
  • 14 Amin MB, Greene FL, Edge SB. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67 (02) 93-99
    CrossrefPubMedGoogle Scholar
  • 15 Siddiqui MRS, Simillis C, Bhoday J. et al. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer 2018; 104: 47-61
    CrossrefPubMedGoogle Scholar
  • 16 Glynne-Jones R, Wyrwicz L, Tiret E. et al; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv22-iv40
    CrossrefPubMedGoogle Scholar
  • 17 Burdan F, Sudol-Szopinska I, Staroslawska E. et al. Magnetic resonance imaging and endorectal ultrasound for diagnosis of rectal lesions. Eur J Med Res 2015; 20 (01) 4
    CrossrefPubMedGoogle Scholar
  • 18 Zhang G, Cai YZ, Xu GH. Diagnostic accuracy of MRI for assessment of T category and circumferential resection margin involvement in patients with rectal cancer: a meta-analysis. Dis Colon Rectum 2016; 59 (08) 789-799
    CrossrefPubMedGoogle Scholar
  • 19 Balyasnikova S, Brown G. Optimal imaging strategies for rectal cancer staging and ongoing management. Curr Treat Options Oncol 2016; 17 (06) 32
    CrossrefPubMedGoogle Scholar
  • 20 Pangarkar SY, Baheti AD, Mistry KA. et al. Prognostic significance of EMVI in rectal cancer in a tertiary cancer hospital in India. Indian J Radiol Imaging 2021; 31 (03) 560-565
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Taylor FGM, Quirke P, Heald RJ. et al; Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014; 32 (01) 34-43
    CrossrefPubMedGoogle Scholar
  • 22 Burghgraef TA, Hol JC, Rutgers ML. et al; MIRECA Study Group. Implications of the new MRI-based rectum definition according to the sigmoid take-off: multicentre cohort study. BJS Open 2023; 7 (02) 18
    CrossrefPubMedGoogle Scholar
  • 23 Santiago I, Figueiredo N, Parés O, Matos C. MRI of rectal cancer-relevant anatomy and staging key points. Insights Imaging 2020; 11 (01) 100
    CrossrefPubMedGoogle Scholar
  • 24 Beets-Tan RGH, Lambregts DMJ, Maas M. et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2018; 28 (04) 1465-1475
    CrossrefPubMedGoogle Scholar
  • 25 Bipat S, Glas AS, Slors FJM, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging–a meta-analysis. Radiology 2004; 232 (03) 773-783
    CrossrefPubMedGoogle Scholar
  • 26 Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004; 54 (06) 295-308
    CrossrefPubMedGoogle Scholar
  • 27 Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008; 26 (02) 303-312
    CrossrefPubMedGoogle Scholar
  • 28 Rödel C, Martus P, Papadoupolos T. et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23 (34) 8688-8696
    CrossrefPubMedGoogle Scholar
  • 29 Nissan A, Stojadinovic A, Shia J. et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol 2006; 24 (25) 4078-4084
    CrossrefPubMedGoogle Scholar
  • 30 Liebig C, Ayala G, Wilks J. et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009; 27 (31) 5131-5137
    CrossrefPubMedGoogle Scholar
  • 31 Quah HM, Chou JF, Gonen M. et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51 (05) 503-507
    CrossrefPubMedGoogle Scholar
  • 32 Nagtegaal ID, Quirke P. Colorectal tumour deposits in the mesorectum and pericolon; a critical review. Histopathology 2007; 51 (02) 141-149
    CrossrefPubMedGoogle Scholar
  • 33 Puppa G, Maisonneuve P, Sonzogni A. et al. Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol 2007; 20 (08) 843-855
    CrossrefPubMedGoogle Scholar
  • 34 Ueno H, Mochizuki H. Clinical significance of extrabowel skipped cancer infiltration in rectal cancer. Surg Today 1997; 27 (07) 617-622
    CrossrefPubMedGoogle Scholar
  • 35 Ueno H, Mochizuki H, Hashiguchi Y. et al. Extramural cancer deposits without nodal structure in colorectal cancer: optimal categorization for prognostic staging. Am J Clin Pathol 2007; 127 (02) 287-294
    CrossrefPubMedGoogle Scholar
  • 36 Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006; 130 (03) 318-324
    CrossrefPubMedGoogle Scholar
  • 37 Tang L, Berlin J, Branton P. et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. College of American Pathologists 2016
    Google Scholar
  • 38 Amin MB, Greene FL, Edge S. , et al , Eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017
    Google Scholar
  • 39 Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006; 8 (09) 800-807
    CrossrefPubMedGoogle Scholar
  • 40 Nagtegaal ID, Marijnen CAM, Kranenbarg EK, van de Velde CJH, van Krieken JHJM. Pathology Review Committee, Cooperative Clinical Investigators. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002; 26 (03) 350-357
    CrossrefPubMedGoogle Scholar
  • 41 Wibe A, Rendedal PR, Svensson E. et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002; 89 (03) 327-334
    CrossrefPubMedGoogle Scholar
  • 42 Compton CC, Fielding LP, Burgart LJ. et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124 (07) 979-994
    PubMedGoogle Scholar
  • 43 Lugli A, Kirsch R, Ajioka Y. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 2017; 30 (09) 1299-1311
    CrossrefPubMedGoogle Scholar
  • 44 Lo DS, Pollett A, Siu LL, Gallinger S, Burkes RL. Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer. Cancer 2008; 112 (01) 50-54
    CrossrefPubMedGoogle Scholar
  • 45 Mayo E, Llanos AAM, Yi X, Duan SZ, Zhang L. Prognostic value of tumour deposit and perineural invasion status in colorectal cancer patients: a SEER-based population study. Histopathology 2016; 69 (02) 230-238
    CrossrefPubMedGoogle Scholar
  • 46 Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol 2003; 84 (03) 127-131
    CrossrefPubMedGoogle Scholar
  • 47 Al-Sukhni E, Attwood K, Gabriel EM, LeVea CM, Kanehira K, Nurkin SJ. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: a retrospective cohort study. Int J Surg 2017; 37: 42-49
    CrossrefPubMedGoogle Scholar
  • 48 Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review. Am J Surg Pathol 2016; 40 (01) 103-112
    CrossrefPubMedGoogle Scholar
  • 49 Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol 2013; 31 (20) 2554-2562
    CrossrefPubMedGoogle Scholar
  • 50 Matloff J, Lucas A, Polydorides AD, Itzkowitz SH. Molecular tumor testing for Lynch syndrome in patients with colorectal cancer. J Natl Compr Canc Netw 2013; 11 (11) 1380-1385
    CrossrefPubMedGoogle Scholar
  • 51 Burt RW. Who should have genetic testing for the Lynch syndrome?. Ann Intern Med 2011; 155 (02) 127-128
    CrossrefPubMedGoogle Scholar
  • 52 Beamer LC, Grant ML, Espenschied CR. et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012; 30 (10) 1058-1063
    CrossrefPubMedGoogle Scholar
  • 53 Cercek A, Lumish M, Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022; 386 (25) 2363-2376
    CrossrefPubMedGoogle Scholar
  • 54 Current issues in colorectal cancer surgery - PubMed. Accessed December 7, 2023 at: https://pubmed.ncbi.nlm.nih.gov/10528898/
    Google Scholar
  • 55 Lindsetmo RO, Joh YG, Delaney CP. Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know. World J Gastroenterol 2008; 14 (21) 3281-3289
    CrossrefPubMedGoogle Scholar
  • 56 Bach SP, Hill J, Monson JRT. et al; Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg 2009; 96 (03) 280-290
    CrossrefPubMedGoogle Scholar
  • 57 Junginger T, Goenner U, Hitzler M. et al. Long-term oncologic outcome after transanal endoscopic microsurgery for rectal carcinoma. Dis Colon Rectum 2016; 59 (01) 8-15
    CrossrefPubMedGoogle Scholar
  • 58 Stornes T, Wibe A, Nesbakken A, Myklebust TA, Endreseth BH. National early rectal cancer treatment revisited. Dis Colon Rectum 2016; 59 (07) 623-629
    CrossrefPubMedGoogle Scholar
  • 59 Clancy C, Burke JP, Albert MR, O'Connell PR, Winter DC. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. Dis Colon Rectum 2015; 58 (02) 254-261
    CrossrefPubMedGoogle Scholar
  • 60 Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007; 25 (08) 1014-1020
    CrossrefPubMedGoogle Scholar
  • 61 You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg 2007; 245 (05) 726-733
    CrossrefPubMedGoogle Scholar
  • 62 Landmann RG, Wong WD, Hoepfl J. et al. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum 2007; 50 (10) 1520-1525
    CrossrefPubMedGoogle Scholar
  • 63 Kidane B, Chadi SA, Kanters S, Colquhoun PH, Ott MC. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum 2015; 58 (01) 122-140
    CrossrefPubMedGoogle Scholar
  • 64 Nash GM, Weiser MR, Guillem JG. et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009; 52 (04) 577-582
    CrossrefPubMedGoogle Scholar
  • 65 Gérard JP, Ortholan C, Benezery K. et al. Contact X-ray therapy for rectal cancer: experience in Centre Antoine-Lacassagne, Nice, 2002-2006. Int J Radiat Oncol Biol Phys 2008; 72 (03) 665-670
    CrossrefPubMedGoogle Scholar
  • 66 Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery–the clue to pelvic recurrence?. Br J Surg 1982; 69 (10) 613-616
    CrossrefPubMedGoogle Scholar
  • 67 Marr R, Birbeck K, Garvican J. et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005; 242 (01) 74-82
    CrossrefPubMedGoogle Scholar
  • 68 Ishihara S, Kanemitsu Y, Murono K. et al. Oncological benefit of lateral pelvic lymph node dissection for rectal cancer treated without preoperative chemoradiotherapy: a multicenter retrospective study using propensity score analysis. Int J Colorectal Dis 2016; 31 (07) 1315-1321
    CrossrefPubMedGoogle Scholar
  • 69 Ma B, Gao P, Wang H. et al. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int J Cancer 2017; 141 (05) 1052-1065
    CrossrefPubMedGoogle Scholar
  • 70 Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 2012; 99 (07) 918-928
    CrossrefPubMedGoogle Scholar
  • 71 Kapiteijn E, Marijnen CA, Nagtegaal ID. et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (09) 638-646
    CrossrefPubMedGoogle Scholar
  • 72 Peeters KCMJ, Marijnen CAM, Nagtegaal ID. et al; Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246 (05) 693-701
    CrossrefPubMedGoogle Scholar
  • 73 Chan E, Wise PE, Chakravarthy AB. Controversies in radiation for upper rectal cancers. J Natl Compr Canc Netw 2012; 10 (12) 1567-1572
    CrossrefPubMedGoogle Scholar
  • 74 Ruppert R, Kube R, Strassburg J. et al; other members of the OCUM Group. Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based multimodal therapy trial. J Am Coll Surg 2020; 231 (04) 413-425.e2
    CrossrefPubMedGoogle Scholar
  • 75 Al-Sukhni E, Milot L, Fruitman M. et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19 (07) 2212-2223
    CrossrefPubMedGoogle Scholar
  • 76 Dworák O. Number and size of lymph nodes and node metastases in rectal carcinomas. Surg Endosc 1989; 3 (02) 96-99
    CrossrefPubMedGoogle Scholar
  • 77 Quirke P, Steele R, Monson J. et al; MRC CR07/NCIC-CTG CO16 Trial Investigators, NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373 (9666) 821-828
    CrossrefPubMedGoogle Scholar
  • 78 Schrag D, Shi Q, Weiser MR. et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med 2023
    Google Scholar
  • 79 Hunter CJ, Garant A, Vuong T. et al. Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment. Ann Surg Oncol 2012; 19 (04) 1199-1205
    CrossrefPubMedGoogle Scholar
  • 80 Ansari N, Solomon MJ, Fisher RJ. et al. Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: trans-Tasman radiation oncology group trial (TROG 01.04). Ann Surg 2017; 265 (05) 882-888
    CrossrefPubMedGoogle Scholar
  • 81 Erlandsson J, Holm T, Pettersson D. et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017; 18 (03) 336-346
    CrossrefPubMedGoogle Scholar
  • 82 Bujko K, Wyrwicz L, Rutkowski A. et al; Polish Colorectal Study Group. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 2016; 27 (05) 834-842
    CrossrefPubMedGoogle Scholar
  • 83 Sauer R, Becker H, Hohenberger W. et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351 (17) 1731-1740
    CrossrefPubMedGoogle Scholar
  • 84 Braendengen M, Tveit KM, Berglund A. et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26 (22) 3687-3694
    CrossrefPubMedGoogle Scholar
  • 85 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
    CrossrefPubMedGoogle Scholar
  • 86 Tabchouri N, Eid Y, Manceau G. et al. Neoadjuvant treatment in upper rectal cancer does not improve oncologic outcomes but increases postoperative morbidity. Anticancer Res 2020; 40 (06) 3579-3587
    CrossrefPubMedGoogle Scholar
  • 87 O'Connell MJ, Colangelo LH, Beart RW. et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014; 32 (18) 1927-1934
    CrossrefPubMedGoogle Scholar
  • 88 Hofheinz RD, Wenz F, Post S. et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13 (06) 579-588
    CrossrefPubMedGoogle Scholar
  • 89 Hüttner FJ, Probst P, Kalkum E. et al. Addition of platinum derivatives to fluoropyrimidine-based neoadjuvant chemoradiotherapy for stage II/III rectal cancer: systematic review and meta-analysis. J Natl Cancer Inst 2019; 111 (09) 887-902
    CrossrefPubMedGoogle Scholar
  • 90 Schmoll HJ, Stein A, Van Cutsem E. et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal Cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol 2021; 39 (01) 17-29
    CrossrefPubMedGoogle Scholar
  • 91 Rödel C, Graeven U, Fietkau R. et al; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16 (08) 979-989
    CrossrefPubMedGoogle Scholar
  • 92 Mohiuddin M, Paulus R, Mitchell E. et al. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys 2013; 86 (03) 523-528
    CrossrefPubMedGoogle Scholar
  • 93 Sclafani F, Gonzalez D, Cunningham D. et al. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst 2014; 106 (07) dju121
    CrossrefPubMedGoogle Scholar
  • 94 Helbling D, Bodoky G, Gautschi O. et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2013; 24 (03) 718-725
    CrossrefPubMedGoogle Scholar
  • 95 Willett CG, Duda DG, di Tomaso E. et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27 (18) 3020-3026
    CrossrefPubMedGoogle Scholar
  • 96 Fernández-Martos C, Pericay C, Losa F. et al. Effect of Aflibercept Plus Modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol 2019; 5 (11) 1566-1573
    CrossrefPubMedGoogle Scholar
  • 97 Cercek A, Goodman KA, Hajj C. et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 2014; 12 (04) 513-519
    CrossrefPubMedGoogle Scholar
  • 98 Chau I, Brown G, Cunningham D. et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24 (04) 668-674
    CrossrefPubMedGoogle Scholar
  • 99 Fernández-Martos C, Pericay C, Aparicio J. et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28 (05) 859-865
    CrossrefPubMedGoogle Scholar
  • 100 Perez K, Safran H, Sikov W. et al. Complete neoadjuvant treatment for rectal cancer: the brown university oncology group CONTRE Study. Am J Clin Oncol 2017; 40 (03) 283-287
    CrossrefPubMedGoogle Scholar
  • 101 Maréchal R, Vos B, Polus M. et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012; 23 (06) 1525-1530
    CrossrefPubMedGoogle Scholar
  • 102 Nogué M, Salud A, Vicente P. et al; AVACROSS Study Group. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011; 16 (05) 614-620
    CrossrefPubMedGoogle Scholar
  • 103 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
    CrossrefPubMedGoogle Scholar
  • 104 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
    CrossrefPubMedGoogle Scholar
  • 105 Conroy T, Etienne PL, Rio E. et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol 2023; 41 (17_suppl): LBA3504-LBA3504
    CrossrefGoogle Scholar
  • 106 Jimenez-Fonseca P, Salazar R, Valenti V, Msaouel P, Carmona-Bayonas A. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial. Ann Oncol 2022; 33 (08) 786-793
    CrossrefPubMedGoogle Scholar
  • 107 van der Valk MJM, Marijnen CAM, van Etten B. et al; Collaborative investigators. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - results of the international randomized RAPIDO-trial. Radiother Oncol 2020; 147: 75-83
    CrossrefPubMedGoogle Scholar
  • 108 Garcia-Aguilar J, Chow OS, Smith DD. et al; Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015; 16 (08) 957-966
    CrossrefPubMedGoogle Scholar
  • 109 Petrelli F, Trevisan F, Cabiddu M. et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 2020; 271 (03) 440-448
    CrossrefPubMedGoogle Scholar
  • 110 Kasi A, Abbasi S, Handa S. et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open 2020; 3 (12) e2030097
    CrossrefPubMedGoogle Scholar
  • 111 Cercek A, Roxburgh CSD, Strombom P. et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018; 4 (06) e180071
    CrossrefPubMedGoogle Scholar
  • 112 van den Broek CBM, Vermeer TA, Bastiaannet E, Rutten HJT, van de Velde CJH, Marijnen CAM. Impact of the interval between short-course radiotherapy and surgery on outcomes of rectal cancer patients. Eur J Cancer 2013; 49 (15) 3131-3139
    CrossrefPubMedGoogle Scholar
  • 113 Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A. Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III trial. Br J Surg 2013; 100 (07) 969-975
    CrossrefPubMedGoogle Scholar
  • 114 Carvalho C, Glynne-Jones R. Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol 2017; 18 (06) e354-e363
    CrossrefPubMedGoogle Scholar
  • 115 Papillon J. Surgical adjuvant therapy for rectal cancer: present options. Dis Colon Rectum 1994; 37 (02) 144-148
    CrossrefPubMedGoogle Scholar
  • 116 Dossa F, Acuna SA, Rickles AS. et al. Association between adjuvant chemotherapy and overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection. JAMA Oncol 2018; 4 (07) 930-937
    CrossrefPubMedGoogle Scholar
  • 117 Hong YS, Nam BH, Kim KP. et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15 (11) 1245-1253
    CrossrefPubMedGoogle Scholar
  • 118 Grothey A, Sobrero AF, Shields AF. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018; 378 (13) 1177-1188
    CrossrefPubMedGoogle Scholar
  • 119 Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2 (07) 501-513
    CrossrefPubMedGoogle Scholar
  • 120 López-Campos F, Martín-Martín M, Fornell-Pérez R. et al. Watch and wait approach in rectal cancer: current controversies and future directions. World J Gastroenterol 2020; 26 (29) 4218-4239
    CrossrefPubMedGoogle Scholar
  • 121 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
    CrossrefPubMedGoogle Scholar
  • 122 Ridolfi TJ, Berger N, Ludwig KA. Low anterior resection syndrome: current management and future directions. Clin Colon Rectal Surg 2016; 29 (03) 239-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 123 Martin LA, Gross ME, Mone MC. et al. Routine endoscopic surveillance for local recurrence of rectal cancer is futile. Am J Surg 2015; 210 (06) 996-1001 , discussion 1001–1002
    CrossrefPubMedGoogle Scholar
  • 124 Seo SI, Lim SB, Yoon YS. et al. Comparison of recurrence patterns between ≤5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol 2013; 108 (01) 9-13
    CrossrefPubMedGoogle Scholar
  • 125 Sargent D, Sobrero A, Grothey A. et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27 (06) 872-877
    CrossrefPubMedGoogle Scholar
  • 126 Primrose JN, Perera R, Gray A. et al; FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014; 311 (03) 263-270
    CrossrefPubMedGoogle Scholar
  • 127 Wille-Jørgensen P, Syk I, Smedh K. et al; COLOFOL Study Group. Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA 2018; 319 (20) 2095-2103
    CrossrefPubMedGoogle Scholar
  • 128 Nicholson BD, Shinkins B, Mant D. Blood measurement of carcinoembryonic antigen level for detecting recurrence of colorectal cancer. JAMA 2016; 316 (12) 1310-1311
    CrossrefPubMedGoogle Scholar
  • 129 Kim JY, Byeon JS. Genetic counseling and surveillance focused on Lynch syndrome. J Anus Rectum Colon 2019; 3 (02) 60-68
    CrossrefPubMedGoogle Scholar
  • 130 Serrano D, Patrignani P, Stigliano V. et al. Aspirin colorectal cancer prevention in Lynch syndrome: recommendations in the era of precision medicine. Genes (Basel) 2022; 13 (03) 460
    CrossrefPubMedGoogle Scholar
  • 131 Pfister DG, Benson III AB, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004; 350 (23) 2375-2382
    CrossrefPubMedGoogle Scholar
  • 132 Patel K, Hadar N, Lee J, Siegel BA, Hillner BE, Lau J. The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review. J Nucl Med 2013; 54 (09) 1518-1527
    CrossrefPubMedGoogle Scholar
  • 133 Chakrabarti S, Kasi AK, Parikh AR, Mahipal A. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). Cancers (Basel) 2022; 14 (13) 3078
    CrossrefPubMedGoogle Scholar